Stephens Consulting’s Astrana Health ASTH Stock Holding History

Stephens Consulting’s Portfolio ASTH Stock Details ASTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$466	–	2048
2025 Q1	$466	Buy	+15	New	+$500	﹤0.01%	934

Other funds holding ASTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Stephens Consulting's ASTH Position: Q2 2025 in Review

Stephens Consulting sold out of Astrana Health (ASTH) in Q2 2025, closing a stake of 15 shares — an estimated $466 sold.

Stephens Consulting first reported a position in ASTH in Q1 2025 and held it in 1 quarter. The position peaked at $466 in Q1 2025. 162 funds tracked by Wall St. Rank hold ASTH as of Q2 2025.

Stephens Consulting reported no remaining Astrana Health position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 15 Astrana Health shares in Q2 2025, an estimated $466.
Stephens Consulting first reported a position in Astrana Health in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Astrana Health position peaked at $466 in Q1 2025.
162 funds tracked by Wall St. Rank held Astrana Health as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.